Is Curaleaf Holdings (TSX:CURA) Undervalued After Its Aurora Bid Response?

Curaleaf Holdings responds to Aurora comments and outlines bid terms

Curaleaf Holdings (TSX:CURA) moved into focus after responding to Aurora Cannabis Inc.'s latest public statements about Curaleaf's offer for Aurora and its comments on shareholder value.

The company highlighted Aurora's share price performance and stated that its proposal offered Aurora investors a substantial premium. Curaleaf also said it remains willing to meet at any time to discuss a potential deal.

Management rejected Aurora's description of prior talks. Curaleaf said there have been no substantive discussions to date and that Aurora has not engaged constructively on the proposal.

See our latest analysis for Curaleaf Holdings.

Curaleaf Holdings' recent approach to Aurora comes as the stock trades at CA$13.45, with a 1-day share price return that declined 2.04%, a 7-day share price return of 3.54% and a year-to-date share price return of 25.23%, while the 1-year total shareholder return is 7.51% and the 5-year total shareholder return remains down 70.13%. This suggests that shorter term momentum has improved compared with a much tougher multi year experience for long term holders.

If this deal talk has you reassessing your watchlist, it can be useful to look at other cannabis related opportunities through the supply chain and check out 3 top founder-led companies

Curaleaf Holdings has sparked fresh interest after its approach to Aurora and a solid year to date share price gain. The real tension now is whether to buy after this run or wait for a clearer valuation gap.

Most Popular Curaleaf Holdings Narrative: 24% Undervalued

The most followed narrative on Curaleaf Holdings compares a fair value of about CA$17.70 to the current CA$13.45 share price, and then links that gap to a long term earnings story built on international expansion and margin recovery.

Rapid expansion and regulatory breakthroughs in international markets, notably the strong sequential and yearly growth in Germany, new entry into Turkey (an 87-million-person underpenetrated market), and advancements such as the first medically certified EU device, meaningfully increase Curaleaf's total addressable market, diversify revenue streams beyond the saturated U.S. market, and are likely to drive sustained long-term revenue growth.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that international growth story? The narrative focuses on revenue expansion, improving margins and a richer earnings multiple. The full breakdown shows exactly how those pieces connect into the CA$17.70 fair value.

Result: Fair Value of CA$17.70 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also need to factor in risks for Curaleaf Holdings, including ongoing net losses and potential shareholder dilution from further capital raises or option exchanges.

Find out about the key risks to this Curaleaf Holdings narrative.

Next Steps

With both risks and rewards in play for Curaleaf Holdings, it makes sense to move quickly and review the numbers yourself. To see a concise summary of both sides, start with these 4 key rewards and 3 important warning signs

Looking for more Curaleaf Holdings investment ideas?

If Curaleaf Holdings has sharpened your focus on where to put fresh capital next, do not stop here. Broader idea hunting can help you build a stronger portfolio.

• Target resilience first and check out 9 resilient stocks with low risk scores that aim to keep portfolio swings more manageable when markets turn choppy.
• Spot quality at a discount by reviewing 15 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their financial profile.
• Hunt for future leaders early and scan the screener containing 8 high quality undiscovered gems before everyone else starts paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com